Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209829 | 1.00 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL7911588 | 1.00 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL16671924 | 1.00 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL19243362 | 1.00 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL3219136 | 0.98 | TDP1 (0.66) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5312822 | 0.93 | TDP1 (0.62) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5162656 | 0.89 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL134329 | 0.89 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL137629 | 0.89 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL343629 | 0.89 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845283-B2 | Methods of producing cancer targeting compounds | INSPYR THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9822064-B2 | Methods of producing cancer treating compounds | INSPYR THERAPEUTICS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160347730-A1 | Methods of Producing Cancer Compounds | GENSPERA, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160347706-A1 | Methods of Producing Cancer Compounds | GENSPERA, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-9446141-B2 | Methods of producing cancer compounds | GENSPERA, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160030589-A1 | Methods of Producing Cancer Compounds | GENSPERA, INC. (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347706-A1 | Methods of Producing Cancer Compounds | HCCS, MYC, SDHA | TDP1 2914/4885MAOA 1403/4885MAOB 962/4885 |
| US-20160347730-A1 | Methods of Producing Cancer Compounds | HCCS, MYC, SDHA | TDP1 2914/4885MAOA 1403/4885MAOB 962/4885 |
| US-20160030589-A1 | Methods of Producing Cancer Compounds | NQO1, CYP21A2, CYP11B2 | TDP1 2132/4885MAOA 895/4885MAOB 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.